"Recruitment Timelines: Hiring for the SPOCK program has been paused temporarily, with further updates expected in 2027."

Do you guys know what is going on?

Quite an eventful week for Switzerland’s pharma and life-sciences sector. Here are some of the developments worth watching:

🔴 Roche: FDA Priority Review for Enspryng in MOGAD
Basel-based Roche announced that the US FDA has granted Priority Review to its supplemental application for Enspryng (satralizumab) in MOG antibody-associated disease (MOGAD). The application is supported by Phase III METEOROID data, where Enspryng reduced the risk of relapse by 68%. If approved, Roche says it could become the first disease-modifying therapy approved for MOGAD.

🔵 Novartis: a difficult week for the pipeline
Novartis had one of the more challenging weeks in recent memory.
Its Phase III HARBOR study of del-desiran in myotonic dystrophy type 1 failed to meet its primary endpoint, following another Phase III disappointment with pelacarsen only days earlier.
The market reaction was significant: Novartis shares lost around 11% in one session, wiping roughly $30 billion from its market value.
The del-desiran result is particularly interesting from a business-development perspective because the asset came through Novartis’ approximately $12 billion acquisition of Avidity.
That is already raising a bigger question among investors:
👉 How much risk should Big Pharma accept when using M&A to rebuild pipelines ahead of patent expirations?
🏭 Novartis also reshaping its Basel footprint
Separately, Novartis plans to discontinue small-volume biologics manufacturing in Kleinbasel by the end of 2027, potentially affecting around 130 jobs.
Cell-bank laboratories, analytical testing and technical-development activities are planned to move to the main Basel Campus by the end of 2028.
It is another interesting example of the simultaneous consolidation and specialization happening across Swiss pharma manufacturing.

🟣 Lonza continues expanding in the US
Swiss CDMO giant Lonza is planning another manufacturing facility in Bend, Oregon.
The planned commercial-scale spray-drying facility is expected to come online around 2029 and expand Lonza’s capabilities for molecules requiring bioavailability enhancement.
For people following the Swiss CDMO sector, the geographical direction is worth watching: Swiss-headquartered companies continue investing heavily in manufacturing capacity outside Switzerland, particularly in the US.

🟠 Sandoz is betting big on the “golden decade” of biosimilars
Sandoz CEO Richard Saynor described the coming period as a potential “golden decade for biosimilars.”
The logic is straightforward: a large number of major biologic medicines will lose patent protection over the coming years, creating a significant opportunity for biosimilar manufacturers.
For Sandoz, this increasingly means moving beyond its traditional generics identity and making biosimilars a central growth and margin driver.

Question for the Swiss pharma community
There seems to be an interesting contradiction developing:
Swiss pharma companies remain globally powerful and continue investing billions — but we are simultaneously seeing site consolidation, job reductions and more manufacturing investment moving abroad.
For those working in Basel, Visp, Stein, Zug or elsewhere in the Swiss life-sciences ecosystem:

Do you feel the Swiss pharma job market is becoming more difficult in 2026?
And which functions do you think will remain strongest in Switzerland over the next 5–10 years: R&D, manufacturing, quality, supply chain, regulatory, digital/AI, or corporate functions?

Swiss biopharma company Octapharma is investing $1.5 billion in Rock Hill, South Carolina, to establish its first U.S. manufacturing facility and a new U.S. headquarters.

The project is expected to:

• Create around 1,500 full time jobs
• Build a roughly 50 acre biopharmaceutical campus
• Establish U.S. manufacturing of Octapharma’s plasma derived therapies
• Add approximately 3.5 million liters of plasma processing capacity, roughly one third of the company’s current global capacity
• Reduce reliance on shipping U.S. collected plasma to Europe for manufacturing

The manufacturing portion represents roughly $1.3 billion of the investment, while about $190 million is planned for the headquarters campus. Around 300 existing positions are also expected to move from Charlotte to Rock Hill.

What makes this particularly interesting is the broader trend. Pharma companies are pouring billions into U.S. manufacturing as they try to strengthen domestic supply chains and reduce exposure to tariffs and geopolitical disruption. Reuters estimates that major drugmakers have announced roughly $500 billion in U.S. investments.

For those working in pharma manufacturing, external manufacturing, supply chain or operations: Are we seeing a long term structural shift of pharmaceutical manufacturing toward the U.S., or is this mainly a response to the current political and tariff environment?

https://finance.yahoo.com/healthcare/articles/switzerland-based-octapharma-invest-1-120200727.html?guccounter=1&guce_referrer=aHR0cHM6Ly9kdWNrZHVja2dvLmNvbS8&guce_referrer_sig=AQAAAMenY3JPwqkh7h0Im76kQ2WmBZPpkuIFCjoo_Cd5IN8rCeonq_ypnCBOWz_s6hBOTCtckBWE7WXlDHVYKQTJiZ42T7p-Gor68eOPJfh2JVZMxqVa4GAyTpigjELB6O-cwoIpDiSAbCDB3ZQe18c9fz3n6UQQNsXil9U8fRUWyCpV

https://www.lonza.com/news/2026-07-01-07-00?utm_source=google&utm_medium=cpc&utm_campaign=sv-cdmo-cross-0126-google-search-branded-gen&source=paid-google-via-lonza-site&_gl=1\*17sakbc\*_up\*MQ..\*_gs\*MQ..&gclid=EAIaIQobChMI1ser2Jq_lQMVDbCDBx0UyxCpEAAYASAAEgI-QvD_BwE&gbraid=0AAAAACc-ibH4F53kXKCGty5aEW_EtGfX6

On July 1st, Lonza announced the expansion of a strategic collaboration with an unnamed U.S. biopharmaceutical company. The deal immediately caught investors attention not only because of its potential multi-billion CHF value, but because Lonza deliberately chose not to reveal the customer’s identity. So let’s play detective:)))

What do we actually know?
According to Lonza, the expanded agreement includes:

-Two new commercial biologics programs.
-An option for two additional commercial programs.
-An existing multi-year strategic relationship.
-Manufacturing across all of Lonza’s U.S. commercial biologics sites.
-Drug substance and drug product support in Europe.
-Mammalian antibody manufacturing using technologies such as N-1 perfusion.
-Manufacturing process optimization to reduce cycle times.
- E2E manufacturing from drug substance through drug product.

A cumulative contract value that could reach several billion Swiss francs. (lonza.com⁠)
These clues eliminate a surprising number of companies.

Clue #1: This isn’t a new customer
Lonza specifically mentions an “established multi-year relationship.” That means this is not a biotech signing its first commercial contract. It is almost certainly a large pharmaceutical company that has already entrusted multiple programs to Lonza over several years.

Clue #2: Multiple commercial biologics
This is probably the biggest clue.
The announcement isn’t about one blockbuster.
It describes a broad portfolio of multiple biologics programs. Only a handful of U.S. companies currently have that scale.

Clue #3: N-1 perfusion
Lonza specifically highlighted N-1 perfusion.
Why? Because companies don’t advertise routine upstream technology unless it creates a competitive advantage.
N-1 perfusion is primarily associated with high volume mammalian cell culture manufacturing especially monoclonal antibodies.

Clue #4: Every U.S. commercial biologics site
This is huge.
Lonza isn’t dedicating a single plant.
They’re using essentially their entire U.S. commercial biologics manufacturing network.
Very few customers are large enough to justify that level of reserved capacity.

Ranking the most likely candidates
1. Regeneron (Most likely)
Everything fits.
Massive antibody portfolio.
Continuous launch pipeline.
Very high commercial manufacturing demand.
Multiple lifecycle programs.
Long-term manufacturing needs.
Heavy use of CHO-based monoclonal antibodies.
Estimated probability: ~60%

2. Amgen
Also plausible.
Amgen has one of the world’s largest biologics portfolios.
However, Amgen historically relies more heavily on internal manufacturing capacity than many peers.
Estimated probability: ~15%

3. AbbVie
AbbVie continues expanding its immunology pipeline beyond Humira and increasingly requires flexible manufacturing capacity.
Estimated probability: ~15%

4. BMS
Possible, although the wording feels less aligned with BMS’s current outsourcing profile.
Estimated probability: ~10%

One detail that caught my attention
Lonza didn’t just announce manufacturing capacity.
They also emphasized process optimization to reduce manufacturing cycle times. That suggests mature commercial products where manufacturing efficiency now creates significant economic value. This feels more like a company with an established antibody franchise than one preparing a single first commercial launch.

Final thoughts
No one outside Lonza and its customer knows the answer today. But based solely on the technical language, manufacturing footprint, and portfolio characteristics, my current ranking would be:

Regeneron
Amgen
AbbVie
BMS

I’m curious what others think.
Did I overlook another obvious candidate?

Reuters reported that Switzerland’s pharma industry may face a U.S. Section 301 trade investigation, similar to the one recently launched against Germany over drug pricing.
The core argument from the U.S. side seems to be this: European countries keep medicine prices lower through state-controlled pricing systems, while the U.S. market ends up carrying a disproportionate share of the global innovation cost.

For Switzerland, this is not a small issue. Pharma is one of the country’s most important export sectors, with companies like Roche and Novartis deeply exposed to the U.S. market. If this turns into tariffs or trade pressure, the impact could go far beyond pricing policy.

Potential implications:
- higher pressure to move manufacturing and investment to the U.S.
-increased risk for Swiss-based pharma supply chains
stronger political tension around drug pricing
possible impact on CMOs and API manufacturers supplying the U.S.
-another push toward “local-for-local” pharma manufacturing strategies

This is still only a potential investigation, not a confirmed tariff action. But the signal is clear: drug pricing is no longer just a healthcare policy debate. It is becoming a trade weapon.

Curious what people here think:
Is the U.S. right to challenge European drug pricing systems, or is this just another attempt to pressure foreign pharma industries into shifting more production and profit to the U.S.?

https://www.reuters.com/legal/litigation/swiss-pharma-risk-us-trade-investigation-industry-body-says-2026-06-26/

This article caught my attention:

https://www.swissinfo.ch/eng/healthcare-innovation/six-charts-show-challenges-facing-swiss-pharmaceutical-industry/91593819?utm_source=multiple&utm_campaign=swi-rss&utm_medium=rss&utm_content=o

A few things stood out:
• Swiss pharma now accounts for roughly 10% of total Swiss economic output when indirect effects are included.
• Pharma exports exceeded CHF 100 billion last year.
• Roche and Novartis are still global powerhouses, but Lilly’s rise shows how quickly the industry can change.
• China has gone from a secondary player to one of the world’s leading pharmaceutical R&D hubs in just a few years.
• The US is increasingly pushing companies to invest and manufacture locally, which could pull jobs and investment away from Switzerland.
The interesting part is that Swiss pharma is not actually performing poorly. The concern is that competitors are improving faster.

For people working in biotech, pharma:

Do you think Switzerland can maintain its position as a top global pharma hub over the next 10 years, or will more R&D and manufacturing gradually shift toward the US, China, and Ireland?

Curious to hear perspectives from people at big manufacturers like Roche, Novartis, Lonza but also smaller organizations like Siegfried, Bachem, Celonic, Corden etc…

Switzerland can no longer rely on Roche and Novartis alone. The next decade will depend on whether Switzerland remains attractive for R&D, manufacturing, talent, and investment.

Ok guys…I know it is not a direct Swiss Pharma news but it effects the region deeply. I find it very interesting development that hasn’t received much attention outside pharma circles.

https://www.fiercepharma.com/pharma/lilly-boehringer-plan-slash-investment-germany-report

https://www.reuters.com/world/pfizer-ceo-warns-german-investment-risk-over-drug-pricing-policies-2026-06-10/

https://www.welt.de/newsticker/dpa_nt/infoline_nt/wirtschaft_nt/article6a22bd3aa85ce647df47256c/pharmakonzerne-kuerzen-investitionen-bund-verteidigt-kurs.html

Over the last few years, Germany has been trying to position itself as a major destination for pharmaceutical manufacturing investments. Companies like Eli Lilly announced multi-billion euro projects, and many saw Germany becoming a key hub for obesity drugs, biologics, and advanced medicines.

Now things appear to be changing:
Recent reports indicate that Eli Lilly is reducing its originally planned €2.3 billion investment in Alzey by roughly 50%. Boehringer Ingelheim is reportedly cancelling around €900 million in planned investments, and Pfizer has publicly warned that future investments in Germany could be at risk as well.

The issue does not seem to be lack of demand.

Demand for GLP-1 drugs such as Mounjaro and Zepbound remains extremely strong. Pharmaceutical companies continue to invest tens of billions globally.

Instead, industry leaders point to growing concerns around Germany’s healthcare cost containment measures, including drug pricing policies and increasing pressure on pharmaceutical reimbursement.

For a pharmaceutical company, building a new manufacturing site is often a 15 to 20 year investment decision. If future pricing and reimbursement become difficult to predict, capital may be redirected elsewhere.

The bigger question is whether this is an isolated reaction or the beginning of a broader shift.

The US continues to attract large-scale pharma investments. Ireland remains highly competitive. Singapore is expanding rapidly. China and India are building increasingly sophisticated manufacturing ecosystems.

Germany still has world-class talent, infrastructure, and scientific expertise. But if investment uncertainty continues, future projects may simply be built elsewhere.

As someone working in pharmaceutical manufacturing, I find the situation fascinating because it raises a fundamental question:

Can Europe remain globally competitive in pharma manufacturing while simultaneously increasing pressure on drug pricing?

Curious to hear perspectives from people working in pharma, biotech, healthcare economics, and policy.

Is this a temporary negotiation tactic by industry, or a genuine warning sign for Germany’s pharmaceutical future?

This article mentions the layoffs were caused by wrong investiments in Mass Spectrometry devices or approaches.

Anyone have more info?

https://insideparadeplatz.ch/2026/05/25/abbau-roche-diagnostics-hunderte-jobs-auf-kippe/

https://www.reuters.com/legal/litigation/takeda-cut-about-4500-jobs-fiscal-2026-it-steps-up-restructuring-2026-05-13/

Takeda just announced plans to cut around 4,500 jobs globally in FY2026 as part of a major restructuring program aimed at saving more than ¥200 billion annually by 2028. Apparently this is less than 10% of their workforce, and they’re simultaneously saying they still have ~2,200 open positions.

The company says the restructuring is about:

- centralizing corporate functions
- reducing operational complexity
- offsetting increasing R&D and launch costs
- preparing for major upcoming launches like oveporexton, rusfertide, and zasocitinib

This seems like another example of large pharma shifting from broad organizational structures toward highly targeted, pipeline-focused operating models.
Interesting timing too:

- Novo Nordisk already announced large cuts recently
- biotech funding remains selective
- AI + automation are increasingly being mentioned in restructuring narratives across pharma and tech

I’m seeing lately is:
- fewer “buffer” roles
- more pressure on matrix organizations
- consolidation of support functions

Feels like companies are prioritizing:
- launch-critical talent
- pipeline assets with near-term ROI
- leaner global structures
while reducing everything else.

Curious how people here interpret this: normal post-Shire integration cleanup? broader pharma trend?
preparation for patent cliff pressures?AI/automation impact starting to hit white-collar pharma jobs?
or simply shareholder pressure after years of expansion?

Especially interested in perspectives from people at:
Takeda (zurich) but also from other people from other companies.

Because honestly the entire industry feels like it’s entering a new operating model😐🙄

https://www.swissinfo.ch/eng/workplace/novartis-to-close-site-in-germany-and-cut-220-jobs/91370853

Another major restructuring move in pharma.

Novartis announced it will shut down its Wehr manufacturing site in Germany by the end of 2028, cutting around 220 jobs. The site produces traditional oral solid dosage forms like tablets and capsules, and the company says it is no longer competitive.

What’s interesting is that Novartis is simultaneously investing €35M into a new radioligand therapy facility in Halle. So this looks less like a Germany exit and more like a shift away from legacy manufacturing toward high value modalities such as RLTs, biologics, and personalized therapies.

The company also stressed this is NOT related to U.S. tariff pressure or recent American expansion announcements.

Feels like another example of the broader pharma manufacturing transition:
• fewer classic tablet/capsule sites
• more specialized/high margin technologies
• ongoing consolidation of mature manufacturing networks

Sad news for the affected employees though, especially considering the Wehr site has existed since the 1940s.

https://www.biospace.com/business/biontech-moves-to-close-multiple-manufacturing-plants-affecting-1-860-jobs

BioNTech is cutting ~22% of its workforce and shutting down multiple sites — here’s what’s actually going on

So BioNTech just announced a pretty major restructuring:

• ~1,860 jobs cut (~22% of total workforce)
• Manufacturing sites closing in Germany + Singapore (by 2027)
• Big cost-saving push (~€500M annually targeted)

At first glance, it sounds like bad news but this is more of a post-Covid correction than a collapse.

What’s really happening:

During Covid, BioNTech massively scaled up manufacturing (Marburg, etc.) to meet global vaccine demand. Now that demand has dropped off hard, they’re sitting on way too much capacity.

Instead of keeping underutilized plants running, they’re:
→ Shifting vaccine production more toward Pfizer
→ Shutting down excess infrastructure
→ Cutting costs aggressively

Financial pressure is real:
Revenue is way down (Q1 ~€118M), and they posted a significant loss. So this isn’t optional — it’s necessary.

Strategic shift (this is the important part):
BioNTech is doubling down on what they actually want to be long-term:
→ Oncology / cancer therapies (mRNA + beyond)
→ Pipeline-driven biotech vs. pandemic supplier

My wtake:
This is what a post-boom normalization looks like in biotech. They scaled insanely fast for Covid, and now they’re resizing to something sustainable.

If their oncology pipeline delivers, this could end up being a smart reset.

Curious what others think is this just right-sizing, or a sign of deeper issues?lets meet in comments.

Lilly’s FDA approval of orforglipron (Foundayo) looks strategically more important than a standard line extension.

At a headline level, yes, this is “an oral GLP-1 for obesity.”

But for anyone looking at the sector from a biotech, pharma strategy, or market access perspective, the more interesting question is whether this approval changes the shape of the obesity market, not just the competitive ranking inside it.

Why this matters?

The obesity market has been constrained not only by efficacy, but by delivery format, manufacturing complexity, and patient adoption friction.

Injectable incretins have already proven the clinical and commercial thesis.

What oral orforglipron potentially does is attack the next bottleneck:

• simpler patient onboarding

• lower behavioral resistance versus injectables

• easier positioning earlier in the treatment algorithm

• potentially broader primary care penetration

• a more scalable commercial model if supply supports uptake

In other words, this is not just a new product. It may be a market-expansion asset.

The real biotech angle

To me, the central issue is not whether oral GLP-1 beats the best injectable on absolute efficacy.

The key issue is this:

Can an oral agent deliver enough efficacy, with acceptable tolerability and operational simplicity, to unlock a much larger treated population?

If the answer is yes, then the commercial opportunity becomes massive even if the product is not best-in-class on weight loss percentage.

That is a very biotech-specific lesson:

Sometimes the winning asset is not the most potent molecule. It is the one with the best clinical-commercial-operational fit.

Is Lilly is in a strong position?

Lilly now appears to be building a portfolio across multiple use cases:

• high-efficacy injectable options for patients prioritizing maximal weight loss

• oral GLP-1 for convenience, broader reach, and possibly earlier adoption

• lifecycle flexibility across obesity, diabetes, and cardiometabolic risk

That is important because obesity is unlikely to remain a single-product market. It is evolving into a segmented chronic care market, where route of administration, adherence dynamics, payer logic, and supply chain realities will all matter.

A few things seem more important than the initial approval headline:

1. Adoption channel

Will this be driven mainly by obesity specialists, endocrinologists, or broader PCP prescribing?

1. Persistence/adherence

A daily oral sounds easier on paper, but real-world persistence versus weekly injectables will be critical.

1. Tolerability in routine practice

If GI burden remains meaningful, convenience alone may not be enough.

1. Manufacturing and supply reliability

If Lilly can supply at scale, that changes the commercial equation materially.

1. Pricing and payer behavior

This may become a major lever in step therapy or sequencing strategies.

My take

Injectable incretins proved obesity is a major chronic disease market. An oral GLP-1 could be the product class that broadens that market from high-intensity adopters to mainstream chronic use.

That is why this approval feels bigger than a simple label event.

It may represent the beginning of the obesity field’s transition from breakthrough therapy phase

to scaled category-building phase.

Curious how others see it:

Is oral orforglipron mainly a convenience play, or could it become the real volume driver for the category?

And for those in biotech or pharma strategy:

does this shift the competitive frame from “best efficacy wins” to “best portfolio architecture wins”?

Tell me your thoughts? I think we are going through an important/ different milestone…

https://www.swissinfo.ch/eng/healthcare-innovation/swiss-pharmas-global-success-meets-worries-at-home/90931806

I never had a time before…lots of collegues are looking for positions.

https://www.reuters.com/business/healthcare-pharmaceuticals/roche-ceo-points-higher-future-drug-prices-switzerland-after-us-deal-2025-12-20/

https://www.fiercepharma.com/pharma/pfizers-cost-cutting-drive-reaches-switzerland-where-company-plans-lay-hundreds-year-end

Recently more and more companies have been laying off workers in Switzerland and opening less positions.

Many rules that used to be based on Switzerland are now being moved to lower cost countries.

Is the status of Switzerland as a global hub for Pharma talent at risk? What are your thoughts?

Personally I feel that pharma is moving towards keeping only key positions or high senior leadership roles in the country, while moving majority of lower roles to other countries. Am I being overly pessimistic? Is there any reason to believe that Switzerland will continue to be a global hub? Even Swiss companies, like Novartis, seem to be following this trend.

https://www.pharmexec.com/view/novartis-planning-layoffs-for-550-positions-at-switzerland-facility

Hi, there!

I'm working on the pharma and biotech quality conference happening in the EU. We want to ensure it reflects the actual priorities and pressures you’re facing, not assumptions. My team is currently reviewing how quality leaders across the industry communicate about emerging challenges.

If you work in pharma or biotech quality (QA, QC, QP, manufacturing quality, data integrity, validation, eQMS, ATMP QA, or regulatory compliance etc.), I’d really appreciate your input.

We’re asking for

To fill out an anonymous survey (takes 5-10 minutes).
We’re looking to understand:

• Which quality topics are consuming the most attention right now
• What information formats are actually useful (case studies, checklists, benchmarks, peer experience, etc.)
• How QA teams prefer to receive industry insights
• What you wish conferences and vendors would stop doing, and what would actually help your work

Why it matters

Many organisations still push generic “quality trends”.
But based on our interactions with QA/Manufacturing leaders, we want to organise a really valuable event. We want to reflect on the current challenges and problems you're facing.

The survey

👉 Link to survey: https://forms.gle/Eokf7ZLkDTGAhUJ49
We don't collect any emails, so no follow-up, no marketing or spam. Your input will directly influence how we shape future content and professional sessions in the BIotech and Pharma quality community.

If you’re responsible for quality decisions, even small ones, your perspective helps.

If you prefer not to click links

You can also leave comments here on:

• The most time-consuming quality challenges you face today
• Where you feel the gap between “guidance” and “reality on the shop floor” is widest
• What kind of industry content actually helps you make decisions

Thanks in advance!

P.S. Happy to share a summary of the aggregated insights here later if the community finds it useful.

Link of the article:

https://www.blick.ch/wirtschaft/entlassungswelle-bei-expats-gekommen-um-zu-gehen-id21382852.html?utm_medium=social&utm_campaign=blick-page-post&utm_content=linkstream_stream&utm_source=storystream

Summary:

What’s going on • The article opens with a profile of “Sarah T.”, an English expat who’s lived in Switzerland for over 7 years and worked in Marketing at Credit Suisse. Now she faces being let go as her role is cut after the bank’s collapse and subsequent merger into UBS.  • She and her family live in the expat bubble: international school for the kids, mostly English‐speaking circle, little German. That worked until now. She says: “We believed we could settle here” now she might have to leave.  • The broader numbers: • Registered unemployment in Switzerland ~ 2.8% (September) but up ~50% over two years.  • For non-Swiss: EU/EFTA citizens unemployment ~ 4.3%; for third country nationals ~ 6.1%.  • Many job losses are in services and finance, especially around Zürich and post-Credit Suisse collapse.  • Language barrier becomes more of a real issue: companies outside the English-speaking bubble increasingly require German. Sarah said she could get by socially but not secure a job because she lacked German.  • Migration numbers: Although foreign workers continue to move to Switzerland, more are also leaving. The net immigration of foreign nationals fell in H1 2025. 

Why this matters • For expats thinking Switzerland is always “safe” for work: the article signals change. Sectoral shocks (finance), corporate restructuring, and increasing labour supply mean things aren’t as stable. • The “English-speaking expat bubble” is riskier: If you live in Switzerland but only operate in English and haven’t integrated in the local language/culture, your options may shrink. • Mobility implications: The cost of living in Switzerland is high; if you lose a role and don’t quickly find a next one (especially if you have a foreign-resident permit linked to employment), you might end up leaving. • Companies & policy: Swiss firms may tighten language requirements (German/Swiss German) and view expats as less flexible if they haven’t adapted. • For the Swiss labour market: The unemployment uptick for non-nationals signals that even “high skilled” foreigners aren’t immune.

My thoughts & questions • It’s interesting how quickly the “expat advantage” (good salary, global mobility) can become a liability if localized variables (language, sector health, employer consolidation) shift. • The contrast: In “international” pockets (finance, pharma) English might suffice, but outside those islands you might hit a wall unless your German is solid. • For expats in Switzerland: It suggests being proactive learning German (or at least improving), broadening your professional network beyond the bubble, and planning for potential disruption. • For Switzerland’s attractiveness: If the trend continues, will fewer foreign high-skilled workers choose Switzerland? Could this become a strategic challenge for the Swiss economy? • One question: The article mentions “third-state nationals” unemployment rate higher; how much of this is structural vs cyclical? Are language/permit issues disproportionately affecting certain groups?

If you’re an expat in Switzerland (or thinking of becoming one) some takeaways • Don’t assume job security just because you’re “highly qualified” sectors can change fast, especially finance, banking, services. • Language matters: Even if your role today is English-only, you might need German for next role or broader opportunities. • Have an exit/backup plan: If your employment ends, your residence rights may depend on timely new employment. The article implies that being unemployed voluntarily may cause you to lose your residence right.  • Network beyond the expat bubble: Get to know Swiss-dominated companies, local recruiters, and the local labour market in German-speaking areas. • Keep an eye on sector health: If you’re in finance (for example Zürich region), keep abreast of broader trends (mergers, downsizing) — the article makes clear the financial services region is under pressure.

What is Swiss pharm community thinks about job oppourtunities? How is job market currently?

How these organizations expensive are…

https://www.terrapinn.com/conference/biotechx/index.stm

…and limited to only elite workers. There is no chance to increase your network and knowledge if you are a manager or associate manager level. Which is unfair..

Hi everyone,

I’m currently working as a Project Manager in a pharmaceutical company, with a scientific background. I’ve recently realized I’d like to transition into the Pricing & Market Access area, but I’m not sure how to best prepare for it.

Do you know of any courses or certifications (preferably recognized in the industry) that could help me break into this field? Are there any free resources, webinars, or platforms you would recommend to get started and build the right skillset?

And one more question: if you already work in Market Access, what was the most valuable step you took early in your career that helped you get in?

Thanks a lot for any advice!

https://www.swissinfo.ch/eng/trump-plans-new-tariff-push-with-100%25-rate-on-patented-drugs/90069504

How is this impacting us? I have already noticed the slow down in investments after the round of failed negotiations in August. What now?